Safety of Prasugrel in Indian patients – Multicentric registry of 1000 cases

• Main Authors: Upendra Kaul, Arvind Sethi, P. Arambam, A.K. Omar, R. Keshava, Sanjeeb Roy, Shuvanan Ray, Rakesh Jaswal, Ripan K. Gupta, Rakesh Rai Sapra, Rane Sandip Keshav, Rajpal Singh, Vineet Bhatia, Vinay Sanghi, Arun Chopra
• Format: Article
• Language: English
• Published: Elsevier 2014-11-01
• Series: Indian Heart Journal
• Subjects: Prasugrel; Bleeding; Safety
• Online Access: http://www.sciencedirect.com/science/article/pii/S0019483214007342

Background: Clopidogrel has been the only available antiplatelet drug used along with aspirin in patients of ACS. In recent years 2 new antiplatelet drugs (Prasugrel and Ticagrelor) have become available. Prasugrel in the dose of 10 mg OD has been found to be more efficacious but with increased risk of major bleeding. For this reason it has not gained widespread usage in ACS patients undergoing PCI. There are no systematic data on the use of Prasugrel in Indian population. Method: This is a prospective, multicentric, hospital registry of 1000 patients with ACS undergoing PCI who were administered Prasugrel. The primary safety endpoint of this study was major and minor bleeding while the efficacy endpoint is the composite of CV death, nonfatal MI, nonfatal stroke up to 30 days after PCI. Patients with high bleeding risk were excluded. Results: Most patients (91%) received loading dose of Prasugrel along with the maintenance dose getting according to the defined protocol. Patients were followed up to 30 days post procedure. Primary efficacy end point was reached in 3 patients only with two of them dying due to possible stent thrombosis and the third requiring revascularization of the target vessel for stent thrombosis. One major and 19 minor bleeding complications were recorded, with access site bleeding in 0.7% & non-access site bleeding in 1.2% of the subjects. Conclusion: Prasugrel was found to be effective & not associated with a high incidence of bleeding in the high risk ACS patients when those at a high bleeding risk were excluded.